LY3537021 + liraglutide

LY3537021 + liraglutide is an investigational combination of two agents administered subcutaneously. **LY3537021** is a long-acting glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, developed to improve the gastrointestinal tolerability associated with glucagon-like peptide 1 (GLP-1) receptor agonist therapy. **Liraglutide** is a GLP-1 receptor agonist already approved for type 2 diabetes and weight management. The combination is being developed and tested for potential additive or synergistic metabolic/endocrine effects, with studies mainly focused on safety, tolerability, and mitigation of gastrointestinal adverse effects related to liraglutide[1][3][5][7].